Novartis: Single-Arm, Open-Label, Ph2 of MBG453 added to Hypomethylating Agent for MDS

Clinical Trial Grant

Duke Scholars

Principal Investigator Carlos Manuel de Castro III Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

April 26, 2022

End Date

December 31, 2026

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

April 26, 2022

End Date

December 31, 2026